Sidley represented ADARx Pharmaceuticals, Inc. on the deal.ADARx Pharmaceuticals, Inc., a clinical-stage biotechnology company developing RNA-targeting therapeutics, announced its US$46 million Series B-1 financing. The proceeds from…
ADARx Pharmaceuticals’ US$46 Million Series B-1 Financing
